The American Society for Clinical Oncology (ASCO) annual meeting took place in a virtual format on 29–31 May 2020. Over the three days, exciting work was presented from across the globe, to continue to advance the oncology field and patient outcomes.
Oncology Central, Future Oncology, The Nanomed Zone and Infectious Diseases Hub have collated our Editors’ highlights in the above ‘Editors’ coffee chat’. Let us know your thoughts on Twitter @OncologyCentral.
ASCO expert opinions
“56% of rare tumors have at least one actionable finding.”
— Stephanie Graff, MD, FACP (@DrSGraff) May 30, 2020
Was such an honor to deliver the @ASCO Opening Address. I shared some thoughts about my talk and 5 key messages while receiving my monthly infusion. It felt like a fitting time to share about being a patient-physician-researcher-caregiver-advocate #ASCO20 #ChasingMyCure pic.twitter.com/v2srwY0GNB
— David Fajgenbaum, MD (@DavidFajgenbaum) May 30, 2020
Preliminary but fascinating data on CART and TCR-T activity on solid tumors. An HPV E7-targeting TCR-T demonstrated sustained clinical in half of the 12 patients treated. Solid tumors are the next frontier for cellular therapy #ASCO20 pic.twitter.com/Dc0osx3WSW
— soria (@jsoriamd) May 31, 2020